IBIO 📈 Analysis and forecast of the company's shares 📉 iBio, Inc.

The company's share price iBio, Inc.

iBio is a biotech company with a unique platform for producing plant-based proteins. Its stock price is a history of efforts to commercialize this technology. The chart reflects high volatility and dependence on contract signings and development news.

Share prices of companies in the market segment - Pharma immune

iBio, Inc. is a biotech company that uses its plant-based platform to rapidly develop and manufacture vaccines and therapeutic proteins. We've categorized it as a Pharmaceutical: Immunology company. The chart below shows how the market values ​​innovative manufacturing technologies in biopharma.

Broad Market Index - GURU.Markets

iBio is a biotech company that uses its plant-based platform to rapidly produce vaccines and therapeutic proteins. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with iBio's performance to assess the state of the sector.

IBIO - Daily change in the company's share price iBio, Inc.

For iBio, Inc., a biotechnology company, daily volatility reflects sensitivity to news about the development of its plant-based platform for producing vaccines and therapeutic proteins, as well as contract news.

Daily change in the price of a set of shares in a market segment - Pharma immune

iBio, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with IBIO's performance, with its unique plant-based drug platform, helps to assess it as a high-risk asset.

Daily change in the price of a broad market stock, index - GURU.Markets

iBio is a biotech company using plant-based systems to rapidly produce vaccines and drugs. This innovative company's shares are driven by research data and new partnerships. Its story exemplifies the biotech sector's contribution to overall volatility.

Annual dynamics of the company's market capitalization iBio, Inc.

For iBio, Inc., year-over-year performance is a story about its unique plant-based platform for biopharmaceutical manufacturing. Its 12-month market cap reflects its strategic pivot toward developing its own oncology drugs, as well as its success in providing contract manufacturing services to other biopharmaceutical companies.

Annual dynamics of market capitalization of the market segment - Pharma immune

iBio, Inc. is a biotech company with a unique platform for producing plant-based proteins. After a period of transformation, its goal is to prove the value of its technology. The chart below shows how the market views its new focus and the potential of its scientific platform relative to the biotech sector.

Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets

iBio, with its unique platform for producing plant-based biopharmaceuticals, is a story of searching for its golden product. Its highly volatile performance compared to the market reflects constant strategic shifts and investor anticipation of the next potential breakthrough, be it vaccines or therapeutic proteins.

Monthly dynamics of the company's market capitalization iBio, Inc.

iBio is a biotech company with a unique platform for producing plant-based proteins. Its monthly performance depends on the progress of its own clinical programs and its ability to secure manufacturing contracts for other companies.

Monthly dynamics of market capitalization of the market segment - Pharma immune

iBio is a biotechnology company using a unique plant-based platform for the rapid development and production of vaccines and therapeutic proteins. The chart below illustrates the overall dynamics in the immunology sector, reflecting the search for new, faster, and cheaper ways to produce complex biologics.

Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets

Shares of biotech companies with unique manufacturing platforms can move on partnership news. The chart below shows the overall sentiment. Is iBio, Inc. living its own life, or does its status as a biotech make it dependent on the general risk appetite?

Weekly dynamics of the company's market capitalization iBio, Inc.

iBio, a biotech company with a unique platform for rapid plant-based protein production (FastPharming), is extremely volatile. Its weekly stock price is reflecting news of development and manufacturing contracts with third-party companies, as well as progress in its own R&D programs.

Weekly dynamics of market capitalization of the market segment - Pharma immune

iBio operates in the biotech sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire segment. This chart will show whether the market perceives iBio as a promising platform player or simply part of the mainstream.

Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets

As a biotech company, iBio, Inc. often defies general market trends. Its fate depends not on GDP or inflation, but on contract awards and research results. The chart below clearly demonstrates how IBIO shares can live a life of their own, separate from the broader market.

IBIO - Market capitalization of the company iBio, Inc.

iBio's chart is a story of transformation and finding its niche in biotech. The company uses a plant-based platform to produce proteins. Its market cap dynamics reflect its attempts to apply this technology to vaccines and drugs, as well as investor skepticism after a series of failures.

IBIO - Share of the company's market capitalization iBio, Inc. within the market segment - Pharma immune

iBio, Inc. uses its plant-based FastPharming platform to rapidly develop and manufacture vaccines and therapeutic proteins. Its market share is based on this unique technology. The chart shows how the market perceives its ability to rapidly respond to new pandemic threats and produce complex drugs.

Market capitalization of the market segment - Pharma immune

iBio is a biotech company with a unique platform for the rapid production of plant-based vaccines and proteins. The chart below shows the market capitalization of the immunology pharmaceutical sector. This is the valuation of this innovative technology, which could accelerate the response to future pandemics.

Market capitalization of all companies included in a broad market index - GURU.Markets

iBio is a biotech company with a platform for rapid production of plant-based proteins, which can be used to create vaccines and drugs. Its market capitalization is a bet on this technology. The chart below shows the economic weight of innovative production platforms.

IBIO - Book value capitalization of the company iBio, Inc.

iBio is built on a unique biotechnology platform. Its book value reflects its patents for plant protein production technology (FastPharming®) and its Texas-based manufacturing facility. The chart below shows how the company is transforming its unique manufacturing base to create new drugs.

IBIO - Share of the company's book capitalization iBio, Inc. within the market segment - Pharma immune

iBio, Inc., a biopharmaceutical company, owns its own biopharmaceutical manufacturing facilities. This infrastructure is its key tangible asset. The S_BCap_Seg chart shows its share of the sector.

Market segment balance sheet capitalization - Pharma immune

iBio is a biotech company with a unique platform for the rapid production of plant-based proteins. This technology may require significant capital investment in greenhouses and equipment. The chart below shows how its innovative production model impacts its asset structure.

Book value of all companies included in the broad market index - GURU.Markets

iBio's assets comprise a plant-based production platform. The company's book value reflects its unique greenhouses and equipment, which use plants rather than bioreactors to produce proteins and vaccines. This provides the foundation for the rapid and scalable development of biopharmaceuticals.

Market capitalization to book capitalization ratio - iBio, Inc.

iBio is a biotech company with a unique platform for rapid plant-based protein production. Its book value reflects this technology and production capacity. Its market capitalization is a volatile valuation of the platform's potential for creating vaccines and therapeutics.

Market to book capitalization ratio in a market segment - Pharma immune

iBio is a biotech company with a platform for rapidly producing proteins from plants. Its value lies in this unique technology. The chart shows how the market perceives the potential of this platform for producing vaccines and therapeutics.

Market to book capitalization ratio for the market as a whole

iBio is a biotech company with a unique platform for rapid plant-based protein production. Its value lies in this technology, which can be used to create vaccines and drugs. The chart shows how the market values ​​this innovative production platform.

IBIO - Company debts iBio, Inc.

iBio, a biotech company with a unique platform for producing plant-based proteins, uses debt to finance its development. This chart shows how the company raises capital for contract manufacturing of biopharmaceuticals and for developing its own oncology and vaccine candidates.

Market segment debts - Pharma immune

iBio is a biotech company with its own platform for rapid production of plant-based proteins. After years of development, it is now pursuing commercial applications for its technology through collaborations with other companies. This chart shows its financial position during this transitional phase.

Market debt in general

The company's debt to book capitalization ratio iBio, Inc.

iBio, Inc. is a biotech company with a platform for the rapid production of plant-based vaccines and proteins. This chart shows how the company is financing its innovative technology. Using debt at a stage when the technology is not yet generating stable revenue is a high-risk strategy aimed at a future breakthrough.

Market segment debt to market segment book capitalization - Pharma immune

iBio, Inc. is a biotech company with a platform for rapid vaccine and protein production. This biotech chart shows how companies finance their innovative manufacturing platforms. It helps assess whether a company's debt is an investment in technology that could transform the pharmaceutical industry.

Debt to book value of all companies in the market

iBio, Inc. is a biotechnology company with a proprietary plant-based platform for the rapid development and production of vaccines and therapeutic proteins. This chart, showing the market's debt-to-book value ratio, is important for assessing the investment climate. The market's willingness to finance innovative production platforms determines iBio's future.

P/E - iBio, Inc.

iBio is a biotech company with a unique platform for rapid production of plant-based proteins. This chart reflects the potential of this technology for creating vaccines and therapeutics. Its value indicates how much investors believe this method will be faster and cheaper than traditional methods, especially during pandemics.

P/E of the market segment - Pharma immune

iBio, Inc. is a biotech company. This chart shows the average P/E ratio for the biotech sector. Comparing the company's P/E to this benchmark allows us to understand how highly the market values ​​its plant-based protein production platform compared to other, more traditional biotech methods.

P/E of the market as a whole

iBio is a biotech company with a unique platform for rapid production of plant-based proteins. This technology can be used to create vaccines and therapeutics. This chart shows the risk appetite in biotech. The company's valuation depends on whether it can demonstrate the benefits of its plant-based platform and secure partnerships to commercialize the technology.

Future (projected) P/E of the company iBio, Inc.

iBio is a biotech company using a plant-based platform for the rapid production of vaccines and proteins. The chart shows expected future revenue, which depends on the successful application of its technology in the development of its own drugs or in partnership with other companies.

Future (projected) P/E of the market segment - Pharma immune

iBio is a biotech company using a plant-based platform to rapidly produce vaccines and therapeutic proteins. This chart shows how its future revenue expectations compare to the industry average, reflecting the market's appreciation of its unique and potentially faster production technology.

Future (projected) P/E of the market as a whole

iBio, Inc. is a biotech company with a platform for rapid production of plant-based proteins. After struggling with vaccine development, the company is seeking new applications for its technology. Its story is not about growth, but about finding a new business model that is unrelated to general market expectations.

Company profit iBio, Inc.

iBio, Inc. is a biotechnology company using its plant-based FastPharming platform to rapidly develop and manufacture vaccines and therapeutic proteins. Its financial metrics reflect R&D expenses and contract manufacturing revenue. This chart illustrates the company's efforts to commercialize its unique technology to address healthcare challenges.

Profit of companies in the market segment - Pharma immune

iBio, Inc. is a biotechnology company using its plant-based FastPharming platform to rapidly develop and manufacture vaccines and therapeutic proteins. This chart shows the profitability of the immunology segment. The company's unique technology can significantly accelerate the development of new drugs. Its success depends on partnerships and commercialization of its developments.

Overall market profit

iBio, Inc. is a biotechnology company with a platform for rapid production of plant-based proteins that can be used to create vaccines and therapeutics. Its potential depends on partnerships and the success of its developments. This chart shows general economic cycles as iBio works to develop flexible and rapid manufacturing technologies.

Future (projected) profit of the company iBio, Inc.

iBio, Inc. is a biotechnology company using a plant-based platform to rapidly develop and manufacture vaccines and therapeutic proteins. This chart reflects analysts' long-term expectations for its unique technology, demonstrating market confidence that plant-based systems can become a competitive alternative to traditional biomanufacturing.

Future (predicted) profit of companies in the market segment - Pharma immune

iBio, Inc. is a biotechnology company with a plant-based platform for the rapid development and production of vaccines and therapeutic proteins. This chart shows profitability forecasts for the immunology pharmaceutical segment. It reflects expectations for innovative manufacturing technologies that can accelerate the development of new drugs.

Future (predicted) profit of the market as a whole

iBio, Inc. is a biotech company with a platform for rapid protein production. Their success depends on contracting and funding development. The overall market revenue forecast, shown in the chart, influences the investment climate and the willingness of pharmaceutical giants to invest in partnerships.

P/S - iBio, Inc.

iBio, Inc. is a biotechnology company with a platform for rapid production of plant-based proteins. Revenue is driven by development and manufacturing contracts. Its price-to-sales ratio reflects how investors view the potential of its unique and rapid production technology.

P/S market segment - Pharma immune

iBio, Inc. is a biotech company using its plant-based FastPharming platform to rapidly develop and manufacture vaccines and therapeutic proteins. Their technology could accelerate pandemic response. The chart shows how the market values ​​their innovative manufacturing platform and development pipeline, including oncology drugs.

P/S of the market as a whole

iBio is a biotech company using a plant-based platform for the rapid production of vaccines and proteins. The company has no stable commercial revenue. This chart, showing its estimated real revenue, emphasizes that iBio is betting on its unique and rapid production technology.

Future (projected) P/S of the company iBio, Inc.

iBio, Inc. is a biotechnology company with a platform for rapid plant-based protein production that can be used to develop vaccines and therapeutics. This chart reflects investor expectations for future revenue from this unique technology, which can be licensed or used to create proprietary products.

Future (projected) P/S of the market segment - Pharma immune

iBio, Inc. is a biotechnology company using its plant-based FastPharming® platform to rapidly develop and manufacture vaccines and therapeutic proteins. This chart shows how the market perceives the future potential of its unique manufacturing technology. It compares it to other immunology companies, reflecting confidence in its innovative approach.

Future (projected) P/S of the market as a whole

iBio is a biotechnology company with a platform for the rapid production of plant-based vaccines and therapeutic proteins. It offers an innovative approach to biopharmaceutical manufacturing. This chart shows overall revenue projections, and iBio illustrates how new manufacturing technologies can transform the pharmaceutical industry.

Company sales iBio, Inc.

iBio, Inc. is a biotechnology company that provides contract manufacturing services for biologics using its unique plant-based platform and also develops its own vaccines and therapeutics. Its revenue in this chart is generated primarily by providing manufacturing services to other pharmaceutical companies.

Sales of companies in the market segment - Pharma immune

iBio is a biotech company with its own platform for rapid protein production. At this stage, its revenue is likely derived from contract manufacturing services for other companies. This chart provides an indication of the demand for its unique manufacturing technology.

Overall market sales

iBio, Inc. is a biotechnology company with a platform for the rapid production of proteins used in vaccines and therapeutics. Its potential depends on contract awards and the successful implementation of its technology. This timeline is not key for the company, unlike news in the biotechnology and pandemic preparedness sectors.

Future (projected) sales of the company iBio, Inc.

iBio is a biotech company with a platform for rapid plant-based protein production, which it uses to develop vaccines and therapeutics. Its revenue forecast depends on the success of its developments and partnerships. This chart shows analyst expectations for its unique technology.

Future (projected) sales of companies in the market segment - Pharma immune

iBio, Inc. is a biotechnology company with a rapid platform for the development and production of plant-based vaccines and therapeutic proteins. This chart shows projected revenue for the entire immunology segment. It reflects the need for flexible and scalable manufacturing capacity, a unique advantage of iBio's technology.

Future (projected) sales of the market as a whole

iBio is a biotech company with a platform for rapid production of plant-based proteins that can be used to create vaccines and therapeutics. Its success depends on partnerships and contracts. This graph of overall market expectations reflects the investment climate, which is important for funding innovative manufacturing platforms.

Company marginality iBio, Inc.

iBio, Inc. is a biotechnology company with a platform for rapid production of plant-based proteins. This timeline reflects its transition from contract manufacturing to in-house drug development. Its future profitability depends on the success of its pharmaceutical programs and licensing of its unique technology.

Market segment marginality - Pharma immune

iBio, Inc. is a biotechnology company using its rapid plant-based platform, FastPharming, to develop and manufacture vaccines and therapeutic proteins. This chart reflects the average profitability in the immunology sector. It allows one to assess the commercial and production advantage that iBio's unique technology can provide compared to traditional methods.

Market marginality as a whole

iBio, Inc. is a biotechnology company with a platform for rapid production of plant-based proteins. This technology can be used to create vaccines and drugs. This profitability chart does not reflect the company's potential, which depends on its ability to commercialize its unique production platform.

Number of employees in the company iBio, Inc.

iBio is a biotech company with a unique platform for the rapid production of plant-based proteins. Its headcount dynamics likely reflect a shift in strategy: from contract manufacturing to in-house drug development. This graph illustrates periods of large contracts and phases of in-house R&D.

Share of the company's employees iBio, Inc. within the market segment - Pharma immune

iBio, Inc. is a biotechnology company using its plant-based FastPharming® platform to rapidly develop and manufacture vaccines and therapeutic proteins. This chart illustrates its innovative manufacturing approach. It reflects the proportion of plant biologists and bioprocess specialists working on revolutionary drug production methods that iBio brings together.

Number of employees in the market segment - Pharma immune

iBio, Inc. is a biotechnology company with a platform for rapid plant-based protein production used for vaccine and drug development. This chart shows employment in the immunology sector. Growth in this field reflects the need for innovative and scalable manufacturing platforms for rapid pandemic response.

Number of employees in the market as a whole

iBio, Inc. is a biotechnology company using plant-based systems to rapidly develop and manufacture vaccines and therapeutic proteins. Innovative production platforms could accelerate responses to future pandemics. This chart shows overall employment, and these companies are at the forefront of the biotech revolution.

Market capitalization per employee (in thousands of dollars) of the company iBio, Inc. (IBIO)

iBio, Inc. is a biopharmaceutical company with a unique protein production platform. Its value lies in the speed and efficiency of this technology. This chart shows how the market values ​​this intellectual capital. The high cost per employee is a premium for technology that can accelerate the development of new drugs.

Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune

iBio is a biotech company with its own platform for rapid protein manufacturing (FastPharming). Its market capitalization per employee reflects the value of both this manufacturing technology and its own development pipeline. A sector comparison helps evaluate its dual business model.

Market capitalization per employee (in thousands of dollars) for the overall market

iBio, Inc. is a biotechnology company with a platform for rapid plant-based protein production. This technology can be used to create vaccines and therapeutics. This chart reflects how the market views the potential of this unique production platform and the team's ability to find commercial applications for it.

Profit per employee (in thousands of dollars) of the company iBio, Inc. (IBIO)

iBio is a biotech company with a unique "rapid pharmaceutical" platform (producing proteins in plants). It is attempting to become both a contract manufacturer (CDMO) and a developer of its own drugs. This negative graph shows how much capital is being burned on staff in an attempt to commercialize this technology.

Profit per employee (in thousands of dollars) in the market segment - Pharma immune

iBio, Inc. is a biotechnology company with a unique FastPharming® platform for the rapid production of proteins used in vaccines and therapeutics. This chart highlights the potential value of their technology. It illustrates how the ability to rapidly produce biologics can create a significant competitive advantage and, consequently, high profit potential.

Profit per employee (in thousands of dollars) for the market as a whole

iBio, Inc. is a biotechnology company with a plant-based FastPharming platform for rapid vaccine and protein production. It also develops its own immuno-oncology drugs. This chart reflects the R&D and operating costs of this unique manufacturing platform per employee.

Sales per company employee iBio, Inc. (IBIO)

iBio, Inc. is a biotech company with a platform for rapid protein production. This chart reflects its transition from a service model to developing its own drugs. Revenue per employee growth will depend on contract wins and clinical success with its own candidates.

Sales per employee in the market segment - Pharma immune

iBio, Inc. (IBIO) is a biotechnology company using its plant-based platform (FastPharming®) to rapidly develop and manufacture vaccines and therapeutic proteins. This chart shows the average revenue per employee in the pharmaceutical segment. Comparing iBio to this benchmark demonstrates how effectively they are monetizing their unique manufacturing platform.

Sales per employee for the market as a whole

iBio (IBIO) is a biotech company with a unique protein manufacturing platform (FastPharming). The company is attempting to monetize this platform by offering it as a CDMO (contract manufacturing operation). This metric reflects how successfully they attract customers to their production facilities.

Shares shorted by company iBio, Inc. (IBIO)

iBio, Inc. is a biotech company with its own plant-based protein production platform (FastPharming). The company has a long history of failed projects. This chart shows that investors don't believe in its technology. "Bears" are betting that its platform is ineffective and that the company will be unable to bring any of its own products to market.

Shares shorted by market segment - Pharma immune

iBio (IBIO) is a biotech company with its own plant-based platform (FastPharming) for drug production. The company is struggling to find its footing after the COVID vaccine debacle. This chart highlights the pessimism in the sector. The surge in shorts across the industry is a bet that iBio's technology is not in demand. Investors don't believe that "lettuce-based drugs" will go mainstream and expect the company to burn through cash.

Shares shorted by the overall market

iBio is a contract biotech manufacturer (CDMO) with its own R&D platform. This chart illustrates the overall market pessimism. For iBio, this is a double whammy: fear of a recession is forcing smaller biotechs (its clients) to cut R&D, and investors are unwilling to fund iBio's own long-term development, demanding profits.

The company's RSI 14 indicator iBio, Inc. (IBIO)

This chart shows iBio's extreme volatility. The company uses its plant-based platform (FastPharming) to produce proteins, exploring applications ranging from vaccines to biologics. "Overheating" (above 70) occurs due to announcements of new partnerships or general hype (as was the case with COVID). The lack of a commercial product and the ongoing need for capital keep the oscillator "oversold."

RSI 14 Market Segment - Pharma immune

iBio uses a unique plant-based platform (FastPharming) for the rapid production of vaccines and biopharmaceuticals. The pharma-immune (biotech) sector thrives on R&D news. RSI_14_Seg shows the overall industry "temperature." It helps us understand: is IBIO's growth driven by their technology or is the entire biotech sector overheated by expectations?

RSI 14 for the overall market

For iBio, a biotech company in the R&D stage, this graph is a lifeline. Its survival depends on funding research. During periods of market euphoria, investors are willing to "buy the dream" and generously fund unprofitable but promising projects. In moments of panic, the money supply is turned off, and investors flee speculative biotechs, creating the risk of a capital shortage for iBio.

Analyst consensus stock price forecast IBIO (iBio, Inc.)

iBio (IBIO) uses its plant-based manufacturing platform (FastPharming) and AI to develop new biologics. This chart shows the average 12-month forecast. It reflects analysts' speculative valuation of this unique combination of technologies and its oncology portfolio.

The difference between the consensus estimate and the actual stock price IBIO (iBio, Inc.)

iBio is a unique biotech company. Its signature feature isn't a specific drug, but rather its FastPharming platform, which uses plants (N. benthamiana) to produce vaccines and antibodies at ultra-fast speeds. This chart measures the gap between the current price and the consensus target price. It shows whether analysts believe this "green" manufacturing platform will be in demand in oncology or future pandemics.

Analyst consensus forecast for stock prices by market segment - Pharma immune

iBio is a "green" biotech company. The company uses a unique R&D platform (FastPharming) that "grows" complex proteins for vaccines and drugs in plants. This chart reflects analysts' overall expectations for the entire immunopharmacology sector, demonstrating whether experts believe this plant-based R&D technology will be successful.

Analysts' consensus forecast for the overall market share price

iBio is a biotech company with a unique plant-based platform (FastPharming) for the rapid production of vaccines and proteins (for example, in tobacco). This chart shows the overall risk appetite in the market. For iBio, a company with an innovative but risky technology, overall market optimism (the rising chart) is critical for attracting capital for R&D.

AKiMA Company Index iBio, Inc.

iBio is a plant-based biotech company. They don't have a single product; their signature feature is a manufacturing platform (FastPharming) that uses genetically modified plants (rather than expensive bioreactors) for rapid R&D and production of proteins (vaccines, antibodies). This chart is a summary indicator of their platform bet. It reflects their (current) inability to monetize this technology.

AKIMA Market Segment Index - Pharma immune

iBio, Inc. (IBIO) is a biotech company that uses its unique plant-based manufacturing platform (FastPharming) to rapidly develop and manufacture vaccines and therapeutic proteins. The chart shows the segment average, helping investors assess how this innovative plant-based technology compares to the sector average.

The AKIM Index for the overall market

iBio is a biotech company using AI and plant-based technologies to discover and produce antibodies (immuno-oncology). This chart, which reflects the market average, provides a macro backdrop. It helps assess how iBio, as it transitions into a drug developer, stacks up against broader economic trends.